Physician profile
David Levy
NPI 1073618187
$5,332.44
in general payments reported to CMS, 2019-2025
27 companies · $98.64 in 2025
The $98.64 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $110 · 2021: $824 · 2022: $847 · 2023: $3,046 · 2024: $244 · 2025: $98.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,750 · Food and Beverage: $639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,750.00 |
| Food and Beverage | $638.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu A/S | $2,750.00 | 2023 | |
| Myriad Genetic Laboratories, INC. | $426.45 | 2021-2023 | Prolaris |
| Ambu INC. | $310.25 | 2021-2025 | |
| Janssen Biotech, INC. | $249.63 | 2021-2023 | Erleada, Akeega, Simponi |
| Astellas Pharma US INC | $220.10 | 2019-2025 | Xtandi, Veozah |
| Sumitomo Pharma America, INC. | $195.56 | 2023-2024 | Orgovyx, Gemtesa |
| Urovant Sciences INC | $171.44 | 2021-2022 | |
| Abbvie INC. | $154.07 | 2019-2023 | |
| Endo Pharmaceuticals INC. | $114.71 | 2019-2022 | |
| Antares Pharma, INC. | $106.56 | 2021-2022 | |
| Coloplast Corp | $95.82 | 2019-2022 | |
| Urogen Pharma, INC. | $76.05 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $67.47 | 2021-2022 | |
| Healthtronics Stone Solutions, LLC | $64.14 | 2020 | |
| Pfizer INC. | $48.77 | 2021-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $48.67 | 2021 | |
| Myovant Sciences INC. | $46.44 | 2021 | |
| Rochester Medical Corporation | $30.00 | 2019 | |
| Travere Therapeutics, INC. | $23.50 | 2021 | |
| Intercept Pharmaceuticals, INC. | $23.00 | 2023 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $20.78 | 2024 | Entyvio |
| Progenics Pharmaceuticals, INC. | $20.00 | 2022 | |
| Blue Earth Diagnostics | $17.02 | 2021 | |
| Angiodynamics, INC. | $14.08 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.76 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $12.66 | 2021 | |
| Amgen INC. | $11.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.